SCHEMBL12414654

SCHEMBL12414654

CC(C)c1ncc(-n2cncn2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.44
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
PCSK9 Q8NBP7 2/20 0.40
BRS3 P32247 1/20 0.36
SYK P43405 1/20 0.34
FBP1 P09467 1/20 0.33
HSP90AA1 P07900 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
LMNA P02545 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32
GRM2 Q14416 1/20 0.31
CYP11B2 P19099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20085577 0.77 CYP2A6 (0.53) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL12414649 0.74 S1PR1 (0.41) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL27859244 0.73 CYP2A6 (0.61) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL1619037 0.72 SMN1; SMN2 (0.55) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL24774435 0.71 CYP2A6 (0.46) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30108582 0.71 CYP2A6 (0.46) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL24774425 0.71 CYP2A6 (0.46) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL12414655 0.70 NOTUM (0.43) KDM4EALDH1A1PCSK9BRS3MAPT
SCHEMBL19992545 0.70 CYP2A6 (0.58) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL13086422 0.69 CYP2A6 (0.47) CYP2A6CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 CYP2A6 58/4885CYP1A2 278/4885CYP2D6 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.